Acadia gives once-rejected Prader-Willi drug a second chance

San Diego-based biotechnology company Acadia Pharmaceuticals on Tuesday announced plans to start a Phase 3 trial of a drug for the rare genetic disease Prader-Willi Syndrome that the Food and Drug Administration rejected last year.